Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Moodys
McKesson
Boehringer Ingelheim
McKinsey
Express Scripts
Colorcon

Last Updated: January 19, 2020

DrugPatentWatch Database Preview

LIDOCAINE HYDROCHLORIDE W/ EPINEPHRINE Drug Profile

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

Which patents cover Lidocaine Hydrochloride W/ Epinephrine, and when can generic versions of Lidocaine Hydrochloride W/ Epinephrine launch?

Lidocaine Hydrochloride W/ Epinephrine is a drug marketed by Abbott, Bel Mar, Dell Labs, Intl Medication, and Watson Labs. and is included in eight NDAs.

The generic ingredient in LIDOCAINE HYDROCHLORIDE W/ EPINEPHRINE is epinephrine; lidocaine hydrochloride. There are twenty-one drug master file entries for this compound. Eleven suppliers are listed for this compound. Additional details are available on the epinephrine; lidocaine hydrochloride profile page.

Summary for LIDOCAINE HYDROCHLORIDE W/ EPINEPHRINE
Drug patent expirations by year for LIDOCAINE HYDROCHLORIDE W/ EPINEPHRINE
Recent Clinical Trials for LIDOCAINE HYDROCHLORIDE W/ EPINEPHRINE

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Walter Reed National Military Medical CenterPhase 3
Epimed InternationalPhase 4
University of Massachusetts, WorcesterPhase 4

See all LIDOCAINE HYDROCHLORIDE W/ EPINEPHRINE clinical trials

US Patents and Regulatory Information for LIDOCAINE HYDROCHLORIDE W/ EPINEPHRINE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Abbott LIDOCAINE HYDROCHLORIDE W/ EPINEPHRINE epinephrine; lidocaine hydrochloride INJECTABLE;INJECTION 083154-001 Approved Prior to Jan 1, 1982 DISCN No No   Start Trial   Start Trial   Start Trial
Watson Labs LIDOCAINE HYDROCHLORIDE W/ EPINEPHRINE epinephrine; lidocaine hydrochloride INJECTABLE;INJECTION 080377-003 Approved Prior to Jan 1, 1982 DISCN No No   Start Trial   Start Trial   Start Trial
Dell Labs LIDOCAINE HYDROCHLORIDE W/ EPINEPHRINE epinephrine; lidocaine hydrochloride INJECTABLE;INJECTION 083389-001 Approved Prior to Jan 1, 1982 DISCN No No   Start Trial   Start Trial   Start Trial
Watson Labs LIDOCAINE HYDROCHLORIDE W/ EPINEPHRINE epinephrine; lidocaine hydrochloride INJECTABLE;INJECTION 085463-001 Approved Prior to Jan 1, 1982 DISCN No No   Start Trial   Start Trial   Start Trial
Bel Mar LIDOCAINE HYDROCHLORIDE W/ EPINEPHRINE epinephrine; lidocaine hydrochloride INJECTABLE;INJECTION 080820-001 Approved Prior to Jan 1, 1982 DISCN No No   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Harvard Business School
Johnson and Johnson
Dow
Medtronic
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.